This document provides a summary of the key findings from a survey of nearly 7,000 prostate cancer patients in Denmark, Finland, Norway, and Sweden. Some of the main conclusions from the survey include:
- Many patients were unaware of common prostate cancer symptoms and a significant number discovered their cancer by chance rather than due to symptoms.
- Treatment for prostate cancer often negatively impacted patients' quality of life and sexual function due to common side effects like erectile dysfunction and incontinence.
- After diagnosis, patients had a more positive outlook on life but also thought more about death and what will happen to their family. Family and friends provided important emotional support.
- Access to information varied between countries, with
The board of Europa Uomo met during the 30th annual meeting of the European Association of Urology in Madrid, Spain from March 20-24, 2015. The summary includes:
1) The board discussed initiatives of the Board and upcoming adoption of a Strategic Plan at their annual general meeting in Warsaw.
2) The article discusses common shortcomings in prostate cancer care across Europe, including limited availability of prostate cancer screening in only four European countries.
3) It provides an overview of contents of the newsletter, including articles on depression and anxiety in prostate cancer patients, clinical trials registration and reporting in Europe, and cancer support services in Ireland.
This document provides a summary of the latest issue of the Europa Uomo newsletter "Did You Know?". It discusses several topics related to prostate cancer including potential changes to PSA screening guidelines in the US, differences in treatment availability across European countries, and the importance of incorporating patient preferences into treatment decisions. It also provides updates on new treatments and clinical trials, and highlights awards and accomplishments of notable figures in prostate cancer research and patient advocacy.
This document provides information about the Europa Uomo Board and contents of its newsletter "Did You Know?".
The Board is led by Chairman Ken Mastris and includes vice chairmen, secretary, treasurer, and other members. The newsletter covers topics like depression and its relationship to anxiety in cancer patients, the humanization of cancer care, and a prostate cancer conference. It also provides updates on the strategic plan to achieve the vision of no man suffering from prostate cancer, and encourages contributions from members.
The document summarizes the activities of Europa Uomo, a European prostate cancer patient organization, including:
- Sweden's Prostate Cancer Alliance has over 10,000 members, an astonishing success attributed to its 26 local groups, good government relations, and cultural differences in willingness to discuss prostate cancer.
- Other member highlights include the UK group Tackle's media outreach and Belgium, Portugal, Slovakia and Spain's patient initiatives.
- The newsletter discusses psychological support, self-esteem, medical standards, and reports on prostate cancer services and outcomes in various European countries.
- Europa Uomo's new Liaison Officers Club allows greater participation in prostate cancer initiatives across Europe.
The document provides information about the Europa Uomo board and organization. It includes an editorial by Malcolm Duncan discussing prostate cancer screening discrepancies between men and women in some European countries. It also includes messages from the Treasurer and Acting Secretary Ken Mastris regarding Europa Uomo's 10th anniversary and goals. The document lists activities and events from various European countries regarding prostate cancer awareness and support.
This document is the February 2014 issue of the newsletter "Europa Uomo / Did You Know?".
It discusses several topics, including the launch of the European Clinical Trials Register for prostate cancer which will provide up-to-date information on clinical trials. It also discusses defining successful cancer care outcomes more broadly than just cure, and how active surveillance and basic medical treatments without curative intent can still provide elements of success for patients. Finally, it notes that prostate cancer is increasingly being viewed as a chronic disease for many patients.
The document summarizes the strategic plan developed by Prof. Louis Denis for Europa Uomo, a prostate cancer advocacy organization. The strategic plan identifies several priorities and objectives over the coming years, including contributing to European policy decisions, improving treatment quality across Europe, increasing awareness of prostate cancer, ensuring financial sustainability, expanding membership in more European countries, and conducting research. The ultimate goal is improving outcomes for prostate cancer patients in Europe. The chairman's letter thanks contributors and welcomes new board members, while expressing regret that Prof. Denis has stepped down as strategic advisor but will remain involved as a liaison officer.
This document summarizes the contents of the Europa Uomo newsletter. It discusses the new board members, debates around PSA screening tests, research on new blood tests that can determine cancer aggressiveness, efforts to improve patient information and education, news from member organizations, and the chairman's strategic plan which will be presented for approval. It focuses on improving awareness, standardizing treatment quality across Europe, and better communication within the network and with external partners.
The board of Europa Uomo met during the 30th annual meeting of the European Association of Urology in Madrid, Spain from March 20-24, 2015. The summary includes:
1) The board discussed initiatives of the Board and upcoming adoption of a Strategic Plan at their annual general meeting in Warsaw.
2) The article discusses common shortcomings in prostate cancer care across Europe, including limited availability of prostate cancer screening in only four European countries.
3) It provides an overview of contents of the newsletter, including articles on depression and anxiety in prostate cancer patients, clinical trials registration and reporting in Europe, and cancer support services in Ireland.
This document provides a summary of the latest issue of the Europa Uomo newsletter "Did You Know?". It discusses several topics related to prostate cancer including potential changes to PSA screening guidelines in the US, differences in treatment availability across European countries, and the importance of incorporating patient preferences into treatment decisions. It also provides updates on new treatments and clinical trials, and highlights awards and accomplishments of notable figures in prostate cancer research and patient advocacy.
This document provides information about the Europa Uomo Board and contents of its newsletter "Did You Know?".
The Board is led by Chairman Ken Mastris and includes vice chairmen, secretary, treasurer, and other members. The newsletter covers topics like depression and its relationship to anxiety in cancer patients, the humanization of cancer care, and a prostate cancer conference. It also provides updates on the strategic plan to achieve the vision of no man suffering from prostate cancer, and encourages contributions from members.
The document summarizes the activities of Europa Uomo, a European prostate cancer patient organization, including:
- Sweden's Prostate Cancer Alliance has over 10,000 members, an astonishing success attributed to its 26 local groups, good government relations, and cultural differences in willingness to discuss prostate cancer.
- Other member highlights include the UK group Tackle's media outreach and Belgium, Portugal, Slovakia and Spain's patient initiatives.
- The newsletter discusses psychological support, self-esteem, medical standards, and reports on prostate cancer services and outcomes in various European countries.
- Europa Uomo's new Liaison Officers Club allows greater participation in prostate cancer initiatives across Europe.
The document provides information about the Europa Uomo board and organization. It includes an editorial by Malcolm Duncan discussing prostate cancer screening discrepancies between men and women in some European countries. It also includes messages from the Treasurer and Acting Secretary Ken Mastris regarding Europa Uomo's 10th anniversary and goals. The document lists activities and events from various European countries regarding prostate cancer awareness and support.
This document is the February 2014 issue of the newsletter "Europa Uomo / Did You Know?".
It discusses several topics, including the launch of the European Clinical Trials Register for prostate cancer which will provide up-to-date information on clinical trials. It also discusses defining successful cancer care outcomes more broadly than just cure, and how active surveillance and basic medical treatments without curative intent can still provide elements of success for patients. Finally, it notes that prostate cancer is increasingly being viewed as a chronic disease for many patients.
The document summarizes the strategic plan developed by Prof. Louis Denis for Europa Uomo, a prostate cancer advocacy organization. The strategic plan identifies several priorities and objectives over the coming years, including contributing to European policy decisions, improving treatment quality across Europe, increasing awareness of prostate cancer, ensuring financial sustainability, expanding membership in more European countries, and conducting research. The ultimate goal is improving outcomes for prostate cancer patients in Europe. The chairman's letter thanks contributors and welcomes new board members, while expressing regret that Prof. Denis has stepped down as strategic advisor but will remain involved as a liaison officer.
This document summarizes the contents of the Europa Uomo newsletter. It discusses the new board members, debates around PSA screening tests, research on new blood tests that can determine cancer aggressiveness, efforts to improve patient information and education, news from member organizations, and the chairman's strategic plan which will be presented for approval. It focuses on improving awareness, standardizing treatment quality across Europe, and better communication within the network and with external partners.
Cancer survival mortality_and_incidence_7_countries_1568689974RamiroCazco2
This study analyzed cancer survival, incidence, and mortality trends for seven cancers in seven high-income countries between 1995-2014 using data from 21 population-based cancer registries. The study found that 1-year and 5-year cancer survival increased across almost all cancer types and countries over this period. Survival was generally higher in Australia, Canada, and Norway than other countries for 2010-2014. Larger survival improvements were seen for younger patients and for cancers with poor prognosis like esophagus, stomach, pancreas, and lung. Progress in cancer control was evident for stomach, colon, lung (males), and ovarian cancers, as shown by increased survival and decreased mortality and incidence over time. However, international survival disparities
An Investigation of the Knowledge and Opinions of British Men Regarding Pros...Jedrik Martinez
The document is a dissertation that investigates the knowledge and opinions of British men regarding prostate cancer. It includes the following key points:
- The study surveyed 25 British men and found that most (76%) lacked knowledge about the causes of prostate cancer, though some knew family history and age were factors.
- Regarding screening and treatment, only 12% knew there is no screening program in the UK, while 68% did not know the treatment options.
- However, the men showed positive attitudes, as 80% were willing to undergo screening, 96% felt comfortable talking about prostate cancer, and most said they would not treat someone with prostate cancer differently.
The document summarizes the activities of the Icelandic Cancer Registry (ICR). It notes that the ICR was established in 1954 by the Icelandic Cancer Society to conduct nationwide cancer registration. It receives data from various sources to register all cancer cases in Iceland. The ICR calculates cancer incidence, mortality and survival rates and conducts epidemiological research on cancer risk factors and prognosis. It collaborates internationally on research and data comparison. The document provides examples of ICR research findings on BRCA2 mutations and their implications for cancer risk and prognosis.
This randomized European study evaluated the effect of prostate-specific antigen (PSA) screening on death from prostate cancer. Over 182,000 men aged 50-74 were randomly assigned to screening via PSA tests every 4 years or a control group without screening. After a median follow-up of 9 years, the rate of death from prostate cancer was 20% lower in the screened group compared to the control group. However, screening led to a high risk of overdiagnosis, with many more cases of prostate cancer diagnosed through screening but a small effect on mortality. 1410 men needed to be screened and 48 extra prostate cancer cases needed to be treated to prevent one death from prostate cancer.
long-term colorrectal-cancer mortality after adenoma removalPascual Marrero
This study evaluated long-term colorectal cancer mortality among over 40,000 patients in Norway who had colorectal adenomas removed between 1993 and 2007. Patients were followed through 2011 to assess mortality. The study found that after a median follow-up of 7.7 years, colorectal cancer mortality was lower among patients who had low-risk adenomas removed and moderately higher among those who had high-risk adenomas removed, compared to the general population. High-risk adenomas were defined as multiple adenomas or adenomas with villous growth patterns or high-grade dysplasia.
HIV prevalence and incidence remain high in peri-urban areas of KwaZulu-Natal, South Africa according to a study of three districts. Cross-sectional surveys found HIV prevalence of 42% in Ladysmith, 46% in Edendale, and 41% in Pinetown. Follow-up cohort studies in these areas then determined HIV incidence rates of 14.8, 6.3, and 7.2 per 100 person-years, respectively. Pregnancy incidence was also high at 5.7, 3.1, and 6.3 per 100 person-years despite high reported contraceptive use. These findings suggest ongoing high risk of HIV transmission in these communities.
HIV prevalence and incidence remain high in peri-urban areas of KwaZulu-Natal, South Africa according to a study of three districts. Cross-sectional surveys found HIV prevalence of 42% in Ladysmith, 46% in Edendale, and 41% in Pinetown. Follow-up cohort studies in these areas measured HIV incidence rates of 14.8, 6.3, and 7.2 per 100 person-years respectively. Pregnancy incidence was also high at 5.7, 3.1, and 6.3 per 100 person-years despite high reported contraceptive use. These findings suggest ongoing high risk of HIV transmission in these communities.
This document provides an outline of the programme for the 33rd Annual Meeting of the International Association of Cancer Registry (IACR) taking place in Mauritius from October 10-14, 2011. The programme includes pre-meeting courses on examining cancer trends and making predictions, and training on the CanReg5 cancer registry software. The conference programme consists of oral presentations divided into sessions covering topics like cancer in Mauritius, infections and cancer, and cancer registration challenges. There will also be poster presentations, a welcome reception, and a gala dinner as part of the social programme.
Pattern of Head and Neck Cancer in a Tertiary Institution in Lagos Nigeriaiosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Cancer Incidence and Survival By Major Ethnic GroupThink Ethnic
This report analyzes cancer incidence and survival rates in England between 2002-2006 by major ethnic group using data from the National Cancer Data Repository, which links cancer registry and hospital data. Some key findings:
1) Overall, non-White ethnic groups had lower cancer incidence than Whites, except for certain cancer sites in specific groups. Asians had higher rates of liver, mouth, and cervical cancers. Black males had higher prostate cancer rates.
2) Black and Asian women had poorer breast cancer survival rates at some ages compared to Whites. Asians had better lung cancer survival. There were no significant differences in colorectal cancer survival.
3) Data limitations included 24% of patients lacking ethnicity data and small
This document summarizes the contents of the September 2016 issue of the newsletter "Did You Know?" published by Europa Uomo.
The newsletter discusses Europa Uomo's new strategic plan and board members. It also summarizes several articles on prostate cancer research, including a rise in aggressive prostate cancer cases, efforts to identify new markers to detect aggressive prostate cancer, and evaluations of PSA testing rates and guidelines. Finally, it previews additional articles on active surveillance and the experiences of patients undergoing active surveillance or treatment.
The search for new markers to identify aggressive prostate cancer
A recent study from the San Raffaele Hospital in Milan aims to identify markers that can more accurately detect aggressive prostate cancer and indicate whether cases require
Background: The incidence of cancers is increasing worldwide, particularly in the developing countries as shown by recent cancer stastics from the WHO. It is even anticipated that with the increase in life expentancy, consequent upon inproved standard of living and globalization, the burden of cancers will increase within this millenium. With respective to cancer of the prostate, it is the most common type of cancer in urology. In developing countries, diagnostic is done at a late stage of evolution. In Cameroon, data on prostate cancer are scanty whereas the incidence of this disease is increasing. Objective: This article is designed to describe the epidemiological features of prostate cancer at the General Hospital of Yaoundé. Patients and methods: A 4-year retrospective study of patients seen with the diagnosis of cancer at the Medical Oncology unit of the Yaoundé General Hospital between January 2012 and December 2015. The demographic pattern (age of patients, socio professional activity, marital status), clinical features (cancer diagnosis), treatment modalities and outcome were studied. Main results: Of the 7 775 patients enrolled in the Medical Oncology Service over the study period, 1.4% (n = 108) cases of prostate cancer were seen. The prevalence over the study period was 1.38% and a relatively large annual growth of cases with an annual average of 27 cases was noted. The average age of patients was 67.82 years with a range of 34-83 years. The commonest presenting symptoms were the urinary frequency (54.63%) whereas the least common were fatigue (05.5%) and straining (03.70%). PSA was obtained in 49 patients, representing about 45.4% of all patients. Only 14 (01.26%) had biopsy reports. Conclusion: Prostate cancer is a major problem facing the aging male, and inadequate facilities make early detection difficult. Therefore, treatment is mainly palliative because of late diagnosis.
What is the current evidence between alcohol and cancer?
Presentation given by Giota Mitrou PhD MSc, Head of Research Funding and Science Activities, World Cancer Research Fund International (WCRF International).
1) New research funded by Cancer Council NSW is investigating why overweight Australians have a higher risk of liver cancer and exploring potential treatments. The research is looking at the role of hormones like adiponectin and sugars in liver cancer development and progression.
2) This research is one of 16 projects receiving over $5.4 million in funding from Cancer Council NSW to support cancer research. The projects will run for three years and involve Australian and international research teams.
3) The research aims to find new ways to prevent and treat liver cancer in order to address rising obesity and liver cancer rates in Australia.
Participation of the population in decisions about their health and in the pr...Pydesalud
Póster presentado por Lilisbeth Perestelo en el congreso Summer Institute for Informed Patient Choice (SIIPC14) celebrado del 25 al 27 de junio de 2014 en Dartmouth, Hanover (EEUU). Web: http://siipc.org
Contacto: lperperr@gobiernodecanarias.org
Presentasjon av Det helsevitenskapelige fakultet, Universitetet i Tromsø. Inneholder utfyllende informasjon om noen utvalgte forskningsprosjekter (bl a Tromsøundersøkelsen, Kvinner og kreft, Telemedisin)
Alcohol intake and breast cancer in the European prospective investigation in...BARRY STANLEY 2 fasd
1) This study investigated the relationship between alcohol intake and breast cancer risk using data from over 330,000 women in the European Prospective Investigation into Cancer and Nutrition cohort study followed for an average of 11 years.
2) The study found a significant association between higher alcohol intake and increased breast cancer risk, with a 4.2% increase in risk for every 10 grams of alcohol consumed per day. Intake of 5-15 grams per day was associated with a 5.9% higher risk compared to intake of 0-5 grams per day.
3) The increased risks were seen for both hormone receptor positive and negative breast tumor subtypes, and the risks were stronger among women who started drinking before their first full
This document is a survey report on understanding of lung cancer among male and female students at Taylor's University. It includes an introduction to lung cancer, the objective of comparing understanding between genders, methodology of distributing surveys to 260 students, statistical analysis of the survey results, and conclusions. The analysis found that female respondents had a slightly better understanding of lung cancer than males, though overall understanding was low. Many were unaware that lung cancer can spread to other organs and that surgery is a primary treatment. The report provides statistics on lung cancer in Malaysia and factors that influence risk.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
More Related Content
Similar to Did you know newsletter spring suppl 2015 (april)
Cancer survival mortality_and_incidence_7_countries_1568689974RamiroCazco2
This study analyzed cancer survival, incidence, and mortality trends for seven cancers in seven high-income countries between 1995-2014 using data from 21 population-based cancer registries. The study found that 1-year and 5-year cancer survival increased across almost all cancer types and countries over this period. Survival was generally higher in Australia, Canada, and Norway than other countries for 2010-2014. Larger survival improvements were seen for younger patients and for cancers with poor prognosis like esophagus, stomach, pancreas, and lung. Progress in cancer control was evident for stomach, colon, lung (males), and ovarian cancers, as shown by increased survival and decreased mortality and incidence over time. However, international survival disparities
An Investigation of the Knowledge and Opinions of British Men Regarding Pros...Jedrik Martinez
The document is a dissertation that investigates the knowledge and opinions of British men regarding prostate cancer. It includes the following key points:
- The study surveyed 25 British men and found that most (76%) lacked knowledge about the causes of prostate cancer, though some knew family history and age were factors.
- Regarding screening and treatment, only 12% knew there is no screening program in the UK, while 68% did not know the treatment options.
- However, the men showed positive attitudes, as 80% were willing to undergo screening, 96% felt comfortable talking about prostate cancer, and most said they would not treat someone with prostate cancer differently.
The document summarizes the activities of the Icelandic Cancer Registry (ICR). It notes that the ICR was established in 1954 by the Icelandic Cancer Society to conduct nationwide cancer registration. It receives data from various sources to register all cancer cases in Iceland. The ICR calculates cancer incidence, mortality and survival rates and conducts epidemiological research on cancer risk factors and prognosis. It collaborates internationally on research and data comparison. The document provides examples of ICR research findings on BRCA2 mutations and their implications for cancer risk and prognosis.
This randomized European study evaluated the effect of prostate-specific antigen (PSA) screening on death from prostate cancer. Over 182,000 men aged 50-74 were randomly assigned to screening via PSA tests every 4 years or a control group without screening. After a median follow-up of 9 years, the rate of death from prostate cancer was 20% lower in the screened group compared to the control group. However, screening led to a high risk of overdiagnosis, with many more cases of prostate cancer diagnosed through screening but a small effect on mortality. 1410 men needed to be screened and 48 extra prostate cancer cases needed to be treated to prevent one death from prostate cancer.
long-term colorrectal-cancer mortality after adenoma removalPascual Marrero
This study evaluated long-term colorectal cancer mortality among over 40,000 patients in Norway who had colorectal adenomas removed between 1993 and 2007. Patients were followed through 2011 to assess mortality. The study found that after a median follow-up of 7.7 years, colorectal cancer mortality was lower among patients who had low-risk adenomas removed and moderately higher among those who had high-risk adenomas removed, compared to the general population. High-risk adenomas were defined as multiple adenomas or adenomas with villous growth patterns or high-grade dysplasia.
HIV prevalence and incidence remain high in peri-urban areas of KwaZulu-Natal, South Africa according to a study of three districts. Cross-sectional surveys found HIV prevalence of 42% in Ladysmith, 46% in Edendale, and 41% in Pinetown. Follow-up cohort studies in these areas then determined HIV incidence rates of 14.8, 6.3, and 7.2 per 100 person-years, respectively. Pregnancy incidence was also high at 5.7, 3.1, and 6.3 per 100 person-years despite high reported contraceptive use. These findings suggest ongoing high risk of HIV transmission in these communities.
HIV prevalence and incidence remain high in peri-urban areas of KwaZulu-Natal, South Africa according to a study of three districts. Cross-sectional surveys found HIV prevalence of 42% in Ladysmith, 46% in Edendale, and 41% in Pinetown. Follow-up cohort studies in these areas measured HIV incidence rates of 14.8, 6.3, and 7.2 per 100 person-years respectively. Pregnancy incidence was also high at 5.7, 3.1, and 6.3 per 100 person-years despite high reported contraceptive use. These findings suggest ongoing high risk of HIV transmission in these communities.
This document provides an outline of the programme for the 33rd Annual Meeting of the International Association of Cancer Registry (IACR) taking place in Mauritius from October 10-14, 2011. The programme includes pre-meeting courses on examining cancer trends and making predictions, and training on the CanReg5 cancer registry software. The conference programme consists of oral presentations divided into sessions covering topics like cancer in Mauritius, infections and cancer, and cancer registration challenges. There will also be poster presentations, a welcome reception, and a gala dinner as part of the social programme.
Pattern of Head and Neck Cancer in a Tertiary Institution in Lagos Nigeriaiosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Cancer Incidence and Survival By Major Ethnic GroupThink Ethnic
This report analyzes cancer incidence and survival rates in England between 2002-2006 by major ethnic group using data from the National Cancer Data Repository, which links cancer registry and hospital data. Some key findings:
1) Overall, non-White ethnic groups had lower cancer incidence than Whites, except for certain cancer sites in specific groups. Asians had higher rates of liver, mouth, and cervical cancers. Black males had higher prostate cancer rates.
2) Black and Asian women had poorer breast cancer survival rates at some ages compared to Whites. Asians had better lung cancer survival. There were no significant differences in colorectal cancer survival.
3) Data limitations included 24% of patients lacking ethnicity data and small
This document summarizes the contents of the September 2016 issue of the newsletter "Did You Know?" published by Europa Uomo.
The newsletter discusses Europa Uomo's new strategic plan and board members. It also summarizes several articles on prostate cancer research, including a rise in aggressive prostate cancer cases, efforts to identify new markers to detect aggressive prostate cancer, and evaluations of PSA testing rates and guidelines. Finally, it previews additional articles on active surveillance and the experiences of patients undergoing active surveillance or treatment.
The search for new markers to identify aggressive prostate cancer
A recent study from the San Raffaele Hospital in Milan aims to identify markers that can more accurately detect aggressive prostate cancer and indicate whether cases require
Background: The incidence of cancers is increasing worldwide, particularly in the developing countries as shown by recent cancer stastics from the WHO. It is even anticipated that with the increase in life expentancy, consequent upon inproved standard of living and globalization, the burden of cancers will increase within this millenium. With respective to cancer of the prostate, it is the most common type of cancer in urology. In developing countries, diagnostic is done at a late stage of evolution. In Cameroon, data on prostate cancer are scanty whereas the incidence of this disease is increasing. Objective: This article is designed to describe the epidemiological features of prostate cancer at the General Hospital of Yaoundé. Patients and methods: A 4-year retrospective study of patients seen with the diagnosis of cancer at the Medical Oncology unit of the Yaoundé General Hospital between January 2012 and December 2015. The demographic pattern (age of patients, socio professional activity, marital status), clinical features (cancer diagnosis), treatment modalities and outcome were studied. Main results: Of the 7 775 patients enrolled in the Medical Oncology Service over the study period, 1.4% (n = 108) cases of prostate cancer were seen. The prevalence over the study period was 1.38% and a relatively large annual growth of cases with an annual average of 27 cases was noted. The average age of patients was 67.82 years with a range of 34-83 years. The commonest presenting symptoms were the urinary frequency (54.63%) whereas the least common were fatigue (05.5%) and straining (03.70%). PSA was obtained in 49 patients, representing about 45.4% of all patients. Only 14 (01.26%) had biopsy reports. Conclusion: Prostate cancer is a major problem facing the aging male, and inadequate facilities make early detection difficult. Therefore, treatment is mainly palliative because of late diagnosis.
What is the current evidence between alcohol and cancer?
Presentation given by Giota Mitrou PhD MSc, Head of Research Funding and Science Activities, World Cancer Research Fund International (WCRF International).
1) New research funded by Cancer Council NSW is investigating why overweight Australians have a higher risk of liver cancer and exploring potential treatments. The research is looking at the role of hormones like adiponectin and sugars in liver cancer development and progression.
2) This research is one of 16 projects receiving over $5.4 million in funding from Cancer Council NSW to support cancer research. The projects will run for three years and involve Australian and international research teams.
3) The research aims to find new ways to prevent and treat liver cancer in order to address rising obesity and liver cancer rates in Australia.
Participation of the population in decisions about their health and in the pr...Pydesalud
Póster presentado por Lilisbeth Perestelo en el congreso Summer Institute for Informed Patient Choice (SIIPC14) celebrado del 25 al 27 de junio de 2014 en Dartmouth, Hanover (EEUU). Web: http://siipc.org
Contacto: lperperr@gobiernodecanarias.org
Presentasjon av Det helsevitenskapelige fakultet, Universitetet i Tromsø. Inneholder utfyllende informasjon om noen utvalgte forskningsprosjekter (bl a Tromsøundersøkelsen, Kvinner og kreft, Telemedisin)
Alcohol intake and breast cancer in the European prospective investigation in...BARRY STANLEY 2 fasd
1) This study investigated the relationship between alcohol intake and breast cancer risk using data from over 330,000 women in the European Prospective Investigation into Cancer and Nutrition cohort study followed for an average of 11 years.
2) The study found a significant association between higher alcohol intake and increased breast cancer risk, with a 4.2% increase in risk for every 10 grams of alcohol consumed per day. Intake of 5-15 grams per day was associated with a 5.9% higher risk compared to intake of 0-5 grams per day.
3) The increased risks were seen for both hormone receptor positive and negative breast tumor subtypes, and the risks were stronger among women who started drinking before their first full
This document is a survey report on understanding of lung cancer among male and female students at Taylor's University. It includes an introduction to lung cancer, the objective of comparing understanding between genders, methodology of distributing surveys to 260 students, statistical analysis of the survey results, and conclusions. The analysis found that female respondents had a slightly better understanding of lung cancer than males, though overall understanding was low. Many were unaware that lung cancer can spread to other organs and that surgery is a primary treatment. The report provides statistics on lung cancer in Malaysia and factors that influence risk.
Similar to Did you know newsletter spring suppl 2015 (april) (20)
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Ear Solutions (ESPL)
Binaural hearing using two hearing aids instead of one offers numerous advantages, including improved sound localization, enhanced sound quality, better speech understanding in noise, reduced listening effort, and greater overall satisfaction. By leveraging the brain’s natural ability to process sound from both ears, binaural hearing aids provide a more balanced, clear, and comfortable hearing experience. If you or a loved one is considering hearing aids, consult with a hearing care professional at Ear Solutions hearing aid clinic in Mumbai to explore the benefits of binaural hearing and determine the best solution for your hearing needs. Embracing binaural hearing can lead to a richer, more engaging auditory experience and significantly improve your quality of life.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
Unlocking the Secrets to Safe Patient Handling.pdf
Did you know newsletter spring suppl 2015 (april)
1. EUROPA UOMO / Did You Know? Spring Suppl. April 2015 1
Contents
p.1 Editorial
p.2 Nordic Prostate Cancer Report 2014
EUROPA UOMO Secretariat
Lange Gasthuisstraat 35-37
2000 Antwerp – Belgium
Tel: +32 3 338 91 51 - Fax: +32 3 338 91 52
E-mail: europauomo@skynet.be
Website: www.europa-uomo.org
Editorial
Malcolm G. Duncan - Newsletter Coordinator
Little needs to be said by us on the conclusion of
the present study, carried out on behalf of the 4
Nordic countries by Kompass Kommunikation,
between September 2013 and April 2014. A copy
of the entire report may be obtained from
http://www.prostatacancerforbundet.com/subP
age1.asp?nodeid=99829. The initiative was
sponsored by Astellas Nordic. The quality of the
survey was also assured by the kind co-operation
of leading Nordic medical experts for prostate
cancer.
The survey involved nearly 7,000 prostate cancer
patients living in one of the four participating
countries, who were recruited either by on-line
website banners, by post or emails, as well as by
questionnaires distributed in hospitals and
clinics. One notable conclusion which was drawn
Newsletter of the 23 European member Forums dedicated to improving knowledge of cancer of the prostate
The European Prostate Cancer Coalition
Did You Know?
Supplement n°2 – Spring 2015
2. EUROPA UOMO / Did You Know? Spring Suppl. April 2015 2
from the survey was the general lack of
awareness on the part of the male population of
this sly and deadly disease. In fact a notable
percentage of patients discovered it quite by
chance. This regrettable shortcoming is common
in most European countries and will be reported
on in the June issue.
The survey also noted the varying reactions to
the news to have contracted prostate cancer and
the important role then played by
partners/wives, families and also by belonging to
a Prostate Cancer Association. One of the most
common observations was the effect of prostate
cancer on their relations to the world around
them and, in particular, their partners/wives,
especially from a sexual point of view.
We therefore invite you all to take advantage of
this possibility to have further insight on this
disease which is already second only to
cardiovascular disorders for the premature death
of the male population, partly due to increasing
longevity.
Nordic Prostate Cancer Report 2014
International/Nordic report
Written by Kompas Kommunikation
Introduction to the Conclusions
Every year, more than 22,000 men in the Nordic
countries are diagnosed with prostate cancer. It
is the most common cancer in men, and more
than 177,000 men in the Nordic countries live
with this disease.
Prostate cancer is cancer of the prostate gland
located below the bladder. The etiology of
prostate cancer is not entirely known, but if the
cancer is detected early, recovery is possible. Not
all prostate cancer patients need treatment,
however.
The Nordic patient survey, commissioned by the
pharmaceutical company Astellas Nordic, was
conducted in cooperation with Danish, Finnish,
Norwegian and Swedish patients associations
assisted by the communications and research
agency Kompas Kommunikation. The study
results will be used in a Nordic information
campaign on prostate cancer, which will
concentrate on patients, treatment options and
quality of life.
Enjoy your reading.
About the study and the respondents
This study was conducted by Kompas
Kommunikation in cooperation with the
prostate-patients associations in Denmark
(Prostatakræftforeningen PROPA), Finland
(Suomen Eturauhassyöpäyhdistys ry), Norway
(Prostatakreftforeningen PROFO) and Sweden
(Prostatacancerfürbundet) together with leading
medical experts within prostate-cancer research:
Michael Borre (Denmark), Antti Rannikko
(Finland), Sophie Fosså (Norway) and Göran
Ahlgren (Sweden). The study, completed
between September 2013 and April 2014, has
been sponsored by Astellas Nordic.
6,916 respondents from Denmark (1,784),
Finland (1,106), Norway (1,222) and Sweden
(2,804) participated. All respondents were
diagnosed with prostate cancer.
The respondents were recruited via online
banners on the websites of the Danish, Finnish,
Norwegian and Swedish patients associations
and via letters and e- mails sent directly to
members of the respective patients associations.
Further, respondents were recruited via paper-
based questionnaires available in hospitals and
clinics in the four countries and generally handed
out at meetings within the framework of the
patients associations. Finally, in Sweden,
respondents were also recruited via the online
respondent-recruitment network, Smart-
response.
With respect to a few of the questions, we
observed variations between respondents
participating via the online survey and the
respondents participating via the paper-based
questionnaires. Since the Finnish survey contains
a more extensive number of responses via paper-
based questionnaires, the results for certain
questions should be treated with some
reservation as regards variations between Finnish
3. EUROPA UOMO / Did You Know? Spring Suppl. April 2015 3
respondents and the other three nationalities.
Thus, in connection with question 2, it appears
that – as compared with respondents from the
other Nordic countries – the average time that
Finnish respondents have been diagnosed with
prostate cancer is considerable longer. Also, the
mean age of respondents recruited via paper-
based questionnaires is higher (72.7 years) than
the mean age of respondents using the online
option (68 years).
Kompas Kommunikation has adjusted the
collected data for the purpose of ensuring the
validity of the results. Thus, this adjustment
entailed the removal of respondents giving
invalid responses; and, likewise, any superfluous
responses from respondents participating in the
survey more than once were removed. All tables
list the number of respondent answers as a total.
Not all respondents answered all questions.
However, any respondents having answered less
than 20% of the survey's principal questions were
removed on the basis of the overall assessment
of the data validity.
This report contains the answers from all four
Scandinavian countries
41% of respondents are Swedish, 26% are
Danish, 18% are Norwegian and 16% are Finnish.
Age-wise, 8% of the respondents are below 60
years, 37% are between 60 and 69 years,
whereas 55% of the respondents are 70 or older.
The survey comprises respondents who are
members of a patients association (PROPA
/PROPO/PROFO/Prostatacancerfürbundet/other)
(86%) and respondents who are not (14%). A
comparison has been made between the
responses of the two groups, and there was no
noticeable variation.
In tables and graphs, all percentages have been
rounded off and listed without decimals, which is
the reason why not all tables and graphs state
sums at 100 percent.
About the study and the respondents
Conclusion
This section comprises the most significant
conclusions drawn from the Nordic survey
among prostate-cancer patients performed in
Denmark, Norway, Sweden and Finland from the
autumn 2013 to the spring of 2014.
Diagnosis
A significant number of the Nordic prostate-
cancer patients are not familiar with the typical
symptoms of prostate cancer. Many are not
aware that back pain (55%), blood in the semen
(44%), blood in the urine (39%), incontinence
(32%) and difficulty in passing urine (16%) may
be symptoms of the disease. Differences among
the countries can, however, be detected. Thus,
27% of the Finnish respondents are not aware
that blood in the urine is a symptom of prostate
cancer, whereas it is almost half of the Swedes
(47%) who are not aware of this. On the other
hand, more than 4 out of 10 (44%) of the Finnish
respondents know about back pain as a
symptom of the disease, while this is only the
case for every fifth (22%) of the Danish
respondents.
4. EUROPA UOMO / Did You Know? Spring Suppl. April 2015 4
Frequently, prostate cancer is detected by pure
chance. Half the patients (49%) detected their
prostate cancer by chance in connection with a
visit to their General Practitioner (GP) for other
reasons; whereas slightly fewer (41%) detected
the disease because they experienced symptoms
which made them seek medical advice. Most
Finnish respondents detected the disease by
pure chance (57%); and, similarly; the Finns rank
highest when it comes to detect symptoms and
seek subsequent medical assistance (49%).
More than 4 out of 10 (44%) of the patients are
not aware that prostate cancer may be
hereditary. Most Swedish respondents are aware
of this (61%) and fewer Norwegian (47%).
Collectively, 3 out of 10 (29%) have experienced
previous cases of prostate cancer in their family,
while an equal number (29%) have no knowledge
as to whether there have been previous cases of
prostate cancer in their family. In this
connection, the variation among the four
countries is only minor.
The diagnosed prostate cancer is received with
mixed feelings. For half the Nordic respondents
(48%), the initial reaction was a determination to
fight and conquer the disease. However, many
(32%) reacted by becoming sad, and a large
number (38%) feared the subsequent
proceedings. There are, however, a number of
variations among the countries. Thus, 4 out of 10
(42%) of the Danish respondents reacted by
becoming sad, whereas this only applied to every
fifth (21%) of the Finnish respondents.
Treatment
In general, the Nordic prostate-cancer patients
feel well-informed about their disease. 3 out of 4
(77%) state that, when diagnosed, the
explanation they received about prostate cancer
and its treatment from their doctor/the
healthcare professionals was satisfactory. A
similar number (76%) feel well-informed about
the disease.
However, 4 out of 10 (36%) have not received
information about new research and new
therapeutic options from their doctor/the
healthcare professionals. This is especially the
case for the Swedish respondents (39%) and to
the least extent for the Finns (23%). At the same
time, many of the Nordic respondents (68%)
would like to have further information about the
disease. In Sweden, the interest in additional
disease information is quite large (80%),
whereas, for Denmark, it is somewhat lower
(56%).
The Nordic patients like to be involved and have
a say in connection with their therapy. By far the
most (88%) prefer to discuss therapeutic options
with their doctor and, subsequently, make a joint
decision concerning their therapy. In this
respect, there are only quite slight variations
among the countries.
Collectively, every fourth patient (23%)
experiences the fact of having met many
different medical practitioners in the course of
their disease, as problematic. This is especially
the case for the Danish respondents (33%),
whereas this issue is significantly less important
in Sweden (15%).
7 out of 10 (71%) of the Nordic respondents are
aware that they are entitled to hear another
doctor's opinion about their treatment options,
whereas every fifth (18%) are not aware of this
option. The highest number of patients (75%),
aware of this option, are Swedes; whereas the
lowest number is constituted by Danes (64%).
Collectively, 30% received a second doctor's
opinion concerning their treatment options; and,
in this respect, the variation among the countries
only amounts to a few percent.
More than half the Nordic prostate-cancer
patients experience their therapy to exert a
negative influence on their quality of life only to
a lesser degree (46%) or not at all (9%), while
38% experience the negative influence to a high
(30%) or very high degree (8%). Collectively, the
least affected patients are the Finns, where only
30% feels that their therapy has had a negative
influence on their quality of life; whereas the
Norwegians are the most affected (48%).
The Nordic patients do, however, experience
considerable side effects in connection with their
prostate-cancer therapy. Erectile dysfunction is
the most frequently experienced side effect
(80%). This is followed by incontinence (38%),
5. EUROPA UOMO / Did You Know? Spring Suppl. April 2015 5
fatigue (31%), and hot flushes (29%). Every fifth
(22%) has experienced the development of
breasts or impaired muscular strength (21%) as a
result of the therapy; whereas a little lower
number of respondents have experienced weight
gains (16%), insomnia (14%), depression (13%) or
faecal incontinence (11%). As to side effects from
the therapy, there are only slight variations
among the countries.
Life with prostate cancer
After being diagnosed with prostate cancer, a
significant number of the Nordic prostate-cancer
patients have developed a more positive outlook
on life. Thus, 2 out of 3 (67%) think more about
living in the moment and enjoy life while they
can still do so. This applies to most Finnish
respondents (73%), and to fewer Norwegians
(56%). Collectively, a little less than half the
respondents (46%) think more about acting out
their dreams; and for 4 out of 10 (40%) every
single extra day counts.
However, some respondents think more about
death (33%) and about what will happen to their
family when they are no longer there (36%).
Most Danes (40%) think about what will happen
to their family, whereas the Finns seem to be the
least worried in this respect (28%).
In general, the Nordic patients feel well
equipped. As many as 9 out of 10 (87%) believe
that they handle their disease well; and 7 out of
10 (72%) feel prepared to live with prostate
cancer for the rest of their lives.
But the disease afflicts virility in all countries.
Collectively, 6 out of 10 (63%) feel that they have
lost part of their virility after being diagnosed
with prostate cancer.
Family and relatives play an important role for
the Nordic patients. Almost 9 out of 10 (85%)
receive emotional support from their family,
while 7 out of 10 (71%) find support from their
friends. At the same time, half the respondents
(51%) feel that their relationship with their
partner/wife has grown closer after being
diagnosed with prostate cancer. This applies to
most Danish respondents (56%) and to the
fewest in Norway (46%).
Collectively, almost 9 out of 10 (85%) mainly
discuss their disease with their partner/wife –
apart from their doctor; and, likewise, their
children also play an important role as
conversation partners (48%). Other than these
parties, however, there is considerable variation
as to with whom the patients in the different
countries mainly prefer to discuss their disease.
Thus, half (50%) of the Finnish respondents
mainly discuss their disease with other prostate-
cancer patients, while this only applies to every
fourth (23%) of the Danish respondents.
Sex life
Prostate-cancer therapy afflicts the sex life of the
patients. 6 out of 10 (60%) of the Nordic
prostate-cancer patients are dissatisfied with
their sex life; and 9 out of 10 (87%) have
experienced problems with the ability to get an
erection after having received prostate-cancer
therapy. Similarly, many have experienced
problems with respect to functioning sexually
(79%) and getting an orgasm (71%).
At the same time, a large number (33-39%)
consider the loss of sexual desire to be
frustrating or to constitute a major problem; or
they are worried that this also frustrates their
partner/wife.
As to the questions focused on sex life, there are
only slight variations among the countries.
Information and counselling
68% of the Nordic patients get information from
their patients association. Most probably, this is
attributable to the fact that most of the survey
respondents (86%) are members of a patients
association. Furthermore, 48% get information
from a urologist, 40% from the internet and 34%
from a hospital doctor. A considerable number,
however, also obtain information from their GP
(29%), from information leaflets (27%) or from
other prostate-cancer patients (25%).
However, the sources of information vary
considerably from country to country. Thus, 6
out of 10 (57%) of the Swedish respondents get
information from a urologist; whereas this only
applies to one third (33%) of the Danish
respondents. On the other hand, half the Danish
get information from a hospital doctor, while it is
only 1 out of 6 (17%) of the Finnish respondents.
6. EUROPA UOMO / Did You Know? Spring Suppl. April 2015 6
Instead, 6 out of 10 (60%) of the Finns get
information from their GP – in contrast to only 3
out of 10 (28%) of the Danish respondents.
New Subscriptions
Please send your request by email to the attention
of Anja Vancauwenbergh (europauomo@skynet.be),
the Newsletter secretary, with the following
information:
Name: ……………………………………………………………………
Organisation/Working place: …………………………………
Country: ………………………………………………………………..
E-mail address:……………………………………………………….
Pertinent category (see below)………………………………
………………………………………………………………………………
Any comment or suggestion, in your e-mail, would
be much appreciated:
………………………………………………………………………………
………………………………………………………………………………
Here are the following categories you may belong
to:
Patient Medical association
Ex patient Public administration
GP (family doctor) Charity organization
Scientific Committee Politician
Pharmaceutical company TV or press
Medical research institute
Multi-Disciplinary Centre/PC Unit
Other (please specify)
Sponsoring institutes
European Association of Urology (EAU)
European School of Oncology (ESO)
Oncology Centre Antwerp (OCA)
'The views in this newsletter are not necessarily the
views of Europa Uomo'
“Did You Know?” European Newsletter contacts and email
Austria: Ekkehard Büchler, efb@gmx.com; Belgium: Henk Van daele, henk.vandaele@telenet.be; Bulgaria: Alexander Marinov,
alpemarinov@abv.bg; Cyprus: Andreas Moyseos, andreas.moyseos@cytanet.com.cy; Czech Republic: Dalibor Pacík, dpacik@fnbrno.cz; Denmark:
K.B. Madsen, madsenkb@mail.dk; Finland: Hannu Tavio, hannu.tavio@gmail.com; France: Roland Muntz, info@anamacap.fr.; Germany: Günter
Feick, g-feick@gmx.de; Hungary: Dr. Tamás Simon MD. Ph.D., simon@rakliga.hu; Ireland: John Dowling; johndeclandowling@gmail.com; Italy:
Malcolm Galloway Duncan, mqi@hotmail.co.uk - europauomo.italy@virgilio.it; Lithuania: Zygimantas Kardelis, karzygis@gmail.com; Norway: Tor
Tausvik, tor@tausvik.no; Poland: Tadeusz Rudzinski, stowarzyszenie.gladiator@poctza.fm; Portugal: Joaquim da Cruz Domingos,
cruzdomingos@netcabo.pt; Romania: Toma Catalin Marinescu, rokapros@yahoo.com; Slovak Republic: Josef Blazek, josef.blazek@vsbm.sk –
uomosk.3@gmail.com; Spain: Jordi Estapé, jestape@fefoc.org; Sweden: Calle Waller, calle.waller@partnershipforeurope.se; Switzerland: Max
Lippuner, mlip@bluewin.ch; The Netherlands: Kees van den Berg, voorzitter@prostaatkankerstichting.nl; United Kingdom: Ken Mastris,
ken.mastris@btinternet.com.